Statins and autoimmune diseases

P. L. Meroni, D. Ventura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Inhibitors of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase or statins are effective lipid lowering drugs. The lipid lowering activity is mainly achieved through reduction of cholesterol synthesis and up-regulation of low density lipoprotein receptors that in turn clear low density lipoproteins and low density lipoprotein precursors from the blood. HMG-CoA reductase competitively blocks mevalonate, the enzyme reaction product that is the precursor not only of cholesterol but also of several non-steroidal isoprenoid compounds. Isoprenoids allow the attachment to the cell membrane of signalling proteins involved in various cell functions; their inhibition explains the so-called pleiotropic effects of statins, which include anti-inflammatory anticoagulant and immunomodulatory properties. Such pleiotropic activities have been suggested to justify the benefits of statin therapy besides the simple reduction in plasma cholesterol levels. Accelerated atherosclerosis has been reported in several autoimmune rheumatic diseases. Non-traditional risk factors for atherosclerosis, such as inflammation, immune-mediated responses and thrombophilia, have been suggested to play a major role in sustaining premature atherosclerosis in autoimmune rheumatic diseases. This review focuses on the potential use of statins as a new therapeutical tool for treating autoimmune rheumatic diseases based on their antiatherosclerotic activity and on their pleiotropic effect on inflammation, haemostasis and the immune responses.

Original languageEnglish
Pages (from-to)278-284
Number of pages7
JournalAPLAR Journal of Rheumatology
Volume7
Issue number3
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Autoimmune Diseases
Rheumatic Diseases
Atherosclerosis
Cholesterol
Terpenes
Coenzyme A
LDL Lipoproteins
Oxidoreductases
Inflammation
Lipids
Mevalonic Acid
Thrombophilia
LDL Receptors
Hemostasis
Anticoagulants
Membrane Proteins
Anti-Inflammatory Agents
Up-Regulation
Enzymes

Keywords

  • Atherosclerosis
  • Autoimmune diseases
  • Immunomodulation
  • Inflammation
  • Statins

ASJC Scopus subject areas

  • Rheumatology

Cite this

Statins and autoimmune diseases. / Meroni, P. L.; Ventura, D.

In: APLAR Journal of Rheumatology, Vol. 7, No. 3, 11.2004, p. 278-284.

Research output: Contribution to journalArticle

Meroni, P. L. ; Ventura, D. / Statins and autoimmune diseases. In: APLAR Journal of Rheumatology. 2004 ; Vol. 7, No. 3. pp. 278-284.
@article{b94f72791d2e458b9f66f4c839587ca5,
title = "Statins and autoimmune diseases",
abstract = "Inhibitors of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase or statins are effective lipid lowering drugs. The lipid lowering activity is mainly achieved through reduction of cholesterol synthesis and up-regulation of low density lipoprotein receptors that in turn clear low density lipoproteins and low density lipoprotein precursors from the blood. HMG-CoA reductase competitively blocks mevalonate, the enzyme reaction product that is the precursor not only of cholesterol but also of several non-steroidal isoprenoid compounds. Isoprenoids allow the attachment to the cell membrane of signalling proteins involved in various cell functions; their inhibition explains the so-called pleiotropic effects of statins, which include anti-inflammatory anticoagulant and immunomodulatory properties. Such pleiotropic activities have been suggested to justify the benefits of statin therapy besides the simple reduction in plasma cholesterol levels. Accelerated atherosclerosis has been reported in several autoimmune rheumatic diseases. Non-traditional risk factors for atherosclerosis, such as inflammation, immune-mediated responses and thrombophilia, have been suggested to play a major role in sustaining premature atherosclerosis in autoimmune rheumatic diseases. This review focuses on the potential use of statins as a new therapeutical tool for treating autoimmune rheumatic diseases based on their antiatherosclerotic activity and on their pleiotropic effect on inflammation, haemostasis and the immune responses.",
keywords = "Atherosclerosis, Autoimmune diseases, Immunomodulation, Inflammation, Statins",
author = "Meroni, {P. L.} and D. Ventura",
year = "2004",
month = "11",
doi = "10.1111/j.1479-8077.2004.00103.x",
language = "English",
volume = "7",
pages = "278--284",
journal = "APLAR Journal of Rheumatology",
issn = "0219-0494",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Statins and autoimmune diseases

AU - Meroni, P. L.

AU - Ventura, D.

PY - 2004/11

Y1 - 2004/11

N2 - Inhibitors of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase or statins are effective lipid lowering drugs. The lipid lowering activity is mainly achieved through reduction of cholesterol synthesis and up-regulation of low density lipoprotein receptors that in turn clear low density lipoproteins and low density lipoprotein precursors from the blood. HMG-CoA reductase competitively blocks mevalonate, the enzyme reaction product that is the precursor not only of cholesterol but also of several non-steroidal isoprenoid compounds. Isoprenoids allow the attachment to the cell membrane of signalling proteins involved in various cell functions; their inhibition explains the so-called pleiotropic effects of statins, which include anti-inflammatory anticoagulant and immunomodulatory properties. Such pleiotropic activities have been suggested to justify the benefits of statin therapy besides the simple reduction in plasma cholesterol levels. Accelerated atherosclerosis has been reported in several autoimmune rheumatic diseases. Non-traditional risk factors for atherosclerosis, such as inflammation, immune-mediated responses and thrombophilia, have been suggested to play a major role in sustaining premature atherosclerosis in autoimmune rheumatic diseases. This review focuses on the potential use of statins as a new therapeutical tool for treating autoimmune rheumatic diseases based on their antiatherosclerotic activity and on their pleiotropic effect on inflammation, haemostasis and the immune responses.

AB - Inhibitors of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase or statins are effective lipid lowering drugs. The lipid lowering activity is mainly achieved through reduction of cholesterol synthesis and up-regulation of low density lipoprotein receptors that in turn clear low density lipoproteins and low density lipoprotein precursors from the blood. HMG-CoA reductase competitively blocks mevalonate, the enzyme reaction product that is the precursor not only of cholesterol but also of several non-steroidal isoprenoid compounds. Isoprenoids allow the attachment to the cell membrane of signalling proteins involved in various cell functions; their inhibition explains the so-called pleiotropic effects of statins, which include anti-inflammatory anticoagulant and immunomodulatory properties. Such pleiotropic activities have been suggested to justify the benefits of statin therapy besides the simple reduction in plasma cholesterol levels. Accelerated atherosclerosis has been reported in several autoimmune rheumatic diseases. Non-traditional risk factors for atherosclerosis, such as inflammation, immune-mediated responses and thrombophilia, have been suggested to play a major role in sustaining premature atherosclerosis in autoimmune rheumatic diseases. This review focuses on the potential use of statins as a new therapeutical tool for treating autoimmune rheumatic diseases based on their antiatherosclerotic activity and on their pleiotropic effect on inflammation, haemostasis and the immune responses.

KW - Atherosclerosis

KW - Autoimmune diseases

KW - Immunomodulation

KW - Inflammation

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=23444452929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23444452929&partnerID=8YFLogxK

U2 - 10.1111/j.1479-8077.2004.00103.x

DO - 10.1111/j.1479-8077.2004.00103.x

M3 - Article

VL - 7

SP - 278

EP - 284

JO - APLAR Journal of Rheumatology

JF - APLAR Journal of Rheumatology

SN - 0219-0494

IS - 3

ER -